Frequency Therapeutics, Inc. (FREQ)

NASDAQ: FREQ · IEX Real-Time Price · USD
2.12
+0.02 (0.95%)
Nov 29, 2022 3:03 PM EDT - Market open

Company Description

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function.

Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue.

The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss.

It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone.

The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited.

Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Frequency Therapeutics, Inc.
Frequency Therapeutics logo
Country United States
Founded 2014
IPO Date Oct 3, 2019
Industry Biotechnology
Sector Health Care
Employees 72
CEO Mr. David Lucchino

Contact Details

Address:
75 Hayden Avenue
Lexington, Massachusetts 02421
United States
Phone 781 315 4600
Website frequencytx.com

Stock Details

Ticker Symbol FREQ
Exchange NASDAQ
Fiscal Year End December
Reporting Currency USD
IPO Price $14.00
CIK Code 0001703647
CUSIP Number 35803L108
ISIN Number US35803L1089
Employer ID 47-2324450
SIC Code 2834

Key Executives

Name Position
David L. Lucchino Co-Founder, President, Chief Executive Officer and Director
Dr. Carl P. LeBel Ph.D. Chief Development Officer
Dr. Quentin McCubbin Ph.D. Chief Manufacturing Officer
Dr. Christopher R. Loose Ph.D. Co­-Founder and Chief Scientific Officer
James P. Abely Associate General Counsel and Secretary
Wendy S. Arnold Chief People Officer
Dr. Dana C. Hilt M.D. Chief Medical Officer
Dr. John L. LaMattina Ph.D. Senior Advisor and Member of PCA Regenerative Medicine Advisory Board
Dr. William W. Chin M.D. Senior Vice President of Translational Medicine
Jason Glashow Senior Vice President of Corporate Affairs

Latest SEC Filings

Date Type Title
Nov 8, 2022 10-Q Quarterly Report
Nov 8, 2022 8-K Current Report
Sep 12, 2022 8-K Current Report
Aug 9, 2022 10-Q Quarterly Report
Aug 9, 2022 8-K Current Report
Jul 12, 2022 8-K Current Report
Jul 8, 2022 SC 13G Statement of acquisition of beneficial ownership by individuals
Jun 23, 2022 8-K Current Report
Jun 10, 2022 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jun 6, 2022 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals